If you’re looking for HIV’s answer to the ALS Ice Bucket Challenge, which raised over US$100 million for the ALS Association, Jack Mackenroth just may have it: the HIV Shower Selfie Challenge. Mackenroth, a famous HIV-positive activist and prior contestant on Project Runway, has partnered with Moovz, a global gay social networking app, to launch the project. Playing to a culture that loves a good selfie, Mackenroth is urging everyone to fight HIV stigma by simply taking a special kind of selfie.
“I was inspired by the use of the word ‘clean,’ especially common in gay culture, to describe oneself as STI/STD free. Indirectly this implies that HIV-positive people are somehow ‘dirty,'” says Mackenroth. “I thought a PG or PG-13 shower selfie or Vine video would be a fun way that everyone could easily show their support for finding a cure on social media by using the hashtag #weareALLclean when they post their photo with the link. They then nominate 3 other people to participate and hopefully donate to the project as well.”
Continue reading and find instruction on how to participate at TheBody.com.
Compared with other high-income Western nations, the United States fares remarkably poorly in getting people with HIV diagnosed, into stable care, on treatment and to an undetectable viral load, aidsmap reports. Researchers conducted an analysis of the “treatment cascade” figures for Australia, British Columbia (statistics for all of Canada were not available), Denmark, France, the Netherlands, the United Kingdom and the United States. Results were presented at the HIV Drug Therapy Glasgow conference in Scotland.
The estimated rates of HIV diagnosis among the countries ranged from a low of 71 percent in British Columbia to a high of 86 percent in Australia, with the United States at 82 percent. The United States had the lowest rate of linkage to care, at 66 percent, and Denmark had the highest at 81 percent. The United States had by far the lowest rate of HIV-positive people retained in care at 37 percent, with British Columbia the next lowest at 57 percent. Australia’s 76 percent care-retention rate was the highest.
Because of the United States’ low retention figures, the remainder of the nation’s figures were also markedly lower than the other countries’. The U.S. rate of people with HIV taking antiretrovirals was 33 percent. The high for that figure was the United Kingdom’s 67 percent. The rates of viral suppression were as follows: the United States, 25 percent; British Columbia, 35 percent; France, 52 percent, the Netherlands, 53 percent, the United Kingdom, 58 percent; Denmark, 59 percent; and Australia, 62 percent.
To read the aidsmap story, click here.
To read the conference abstract, click here.
The Allegheny County Health Department has documented an alarming, ongoing increase in Syphilis infections among men who have sex with men in the greater Pittsburgh area. Syphilis is a sexually transmitted disease that, if untreated, can cause serious health problems. You can get Syphilis and not have any initial symptoms so the only way to know you’re infected is to get a simple blood test. Syphilis is 100% curable.
The Health Department suggests all sexually active gay and bi men get tested for Syphilis. To find free testing near you, go to https://gettested.cdc.gov/.
You can also call the Allegheny Health Department to find out more about getting a free test: (412) 578-8332.
To find out more about Syphilis go to the CDC Website at http://www.cdc.gov/std/syphilis/
To read the official Allegheny Health Department press release, Syphilis health alert November 17 2014.
The number of people using Truvada for pre-exposure prophylaxis (PrEP) in the US is increasing and a growing proportion of users are men, according to an analysis of data from approximately half of American pharmacies presented this week at the HIV Drug Therapy Glasgow conference.
PrEP refers to the use of antiretroviral medications to prevent HIV infection. Gilead Sciences’ Truvada(tenofovir + emtricitabine) taken once daily was shown to be effective in the iPrEx study of mostly gay and bisexual men, reducing the risk of HIV infection by 42% overall, rising to 92% among participants with blood drug levels indicating regular use. A mathematical model suggested that taking Truvadafour times per week would provide 99% protection, and in an open-label extension of iPrEx none of the men who took Truvada at least this often became infected.
The US Food and Drug Administration (FDA) approved once-daily Truvada for PrEP in July 2012. In May of this year, the US Centers for Disease Control and Prevention (CDC) recommended that people at ‘substantial risk’ should consider PrEP to prevent HIV infection, and the World Health Organization (WHO) has also recommended PrEP as an option for at-risk gay men.
Yet uptake of Truvada PrEP has not been as widespread as many had hoped, facing barriers such as lack of awareness among people at risk for HIV, resistance from some medical providers and inconsistent insurance coverage.
Continue reading on aidsmap.com.